Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoricoxib vs Naproxen in Ankylosing Spondylitis
NCT01208207Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Sep 2010
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of etoricoxib in ankylosing spondylitis (AS) (4 arms), sponsored by Organon & Co. Primary endpoints: Time-Weighted Average Change From Baseline in the Spinal Pain Intensity at 6 weeks and Number of Participants Discontinuing Study Treatment Due to an Adverse Event at 26 weeks. Started Sep 2010; status: completed.
02
Drugs
etoricoxib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT01208207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208207.